Mr. Robert Charles Duke, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2310 N Highway 66, Suite A, Catoosa, OK 74015 Phone: 918-266-3411 Fax: 918-266-3412 |
Vision & Eye Medical Diagnostic & Laser Center, Inc. Optometrist - Corneal and Contact Management Medicare: Not Enrolled in Medicare Practice Location: 2319 N. Highway 66, Catoosa, OK 74127 Phone: 918-266-3411 Fax: 918-266-3412 |
Eyecare Of Catoosa Hills Optometrist Medicare: Medicare Enrolled Practice Location: 2036 S Miller Ln, Suite E, Catoosa, OK 74015 Phone: 918-266-3937 Fax: 918-266-4019 |
Vision & Eye Medical Diagnostic Laser Center Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2310 North Hwy 66, Suite A, Catoosa, OK 74015 Phone: 918-266-3411 Fax: 918-266-3412 |
Vision And Eye Medical Diagnostic Laser Center Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2310 N Highway 66, Catoosa, OK 74015 Phone: 918-266-3411 Fax: 918-266-3412 |
News Archive
Dimension Therapeutics, a company focused on developing novel adeno-associated virus (AAV) gene therapy treatments for rare diseases, today announced it has entered into a collaboration with Bayer HealthCare (Bayer) for the development and commercialization of a novel gene therapy for the treatment of hemophilia A.
Patients at high risk for a heart attack or stroke who took an investigational drug in addition to a statin had significantly lower LDL, or "bad" cholesterol, after 12 weeks compared to similar patients who took a placebo in addition to statin therapy, according to research presented at the American College of Cardiology's 68thAnnual Scientific Session.
Children delivered by cesarean section and those given antibiotics during early infancy appear more prone to developing allergic inflammation of the esophagus — the muscular tube that connects the mouth to the stomach — according to results of a study by investigators from the Johns Hopkins Children's Center and Harvard Medical School.
Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs), today announces it has entered into a multi-step collaboration with XOMA Corporation, a leader in the discovery and development of therapeutic antibodies.
Supersaturated oxygen (SSO2) administered during catheter-based treatments for heart attack can significantly reduce heart muscle damage, according to a new study reported in Circulation: Cardiovascular Interventions, a journal of the American Heart Association.
› Verified 2 days ago